CARLSBAD, Calif.--(BUSINESS WIRE)--May 19, 2003-- The Immune Response Corporation (Nasdaq:IMNR - News) today announced the forthcoming publication of results from a trial involving REMUNE® by the peer-reviewed journal AIDS. The trial, while enrolling only a limited number of patients, concluded that vaccination with REMUNE® increased HIV-1 specific immune response in chronic HIV patients receiving suppressive antiretroviral therapy (ART). Its authors, led by Dr. Bruce Walker, director of the AIDS Research Center at Massachusetts General Hospital, affiliated with Harvard Medical School, stated that further studies were warranted in light of these findings.
ADVERTISEMENT
"We welcome the intense peer review that preceded the publication of these results," commented John N. Bonfiglio, Ph.D., chief executive officer of The Immune Response Corporation. "Our newly established Scientific Advisory Board will use this data to help design future trials of REMUNE® in order to help accomplish our mission of establishing REMUNE®'s clinical benefit."
Specifically, the trial -- which was investigator-initiated and designed, double blinded and placebo-controlled -- demonstrated the induction of HIV-specific lymphocyte proliferation in all the chronically infected subjects who received REMUNE® and in none of those who received placebo. A total of 10 subjects participated, all of whom had viral loads controlled to less than 500 copies/ml for at least six months and CD4 cell counts of greater than 250 cells/mrn before starting ART.
While The Immune Response Corporation provided financial support and some reagents for the trial, the investigators generated, maintained and analyzed all related data using rigorous, prospectively defined criteria. The Immune Response Corporation did not participate in the preparation of the manuscript.
Trial data was originally presented at the XIV International AIDS Conference in Barcelona, Spain.
About The Immune Response Corporation and REMUNE®
Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company dedicated to treating HIV and AIDS through the development of REMUNE®. REMUNE® is an immune-based therapeutic vaccine designed to induce an HIV-specific immune response and boost the body's natural defense mechanisms in order to slow the virus' progression. REMUNE® is comprised of HIV that has been chemically killed and inactivated so that it is non-infectious. During the inactivation process, the HIV outer envelope, which is prone to rapid mutations, is removed. REMUNE® is then emulsified in Incomplete Freund's Adjuvant, an agent that elicits a more potent immune response by drawing the immune system's attention to the inactivated virus.
HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body's immune system, making it vulnerable to infections. More than 60 million people have been infected with HIV since it was first recognized in 1981. Today, 40 million people around the world are living with HIV.
QADSAN
ADVERTISEMENT
"We welcome the intense peer review that preceded the publication of these results," commented John N. Bonfiglio, Ph.D., chief executive officer of The Immune Response Corporation. "Our newly established Scientific Advisory Board will use this data to help design future trials of REMUNE® in order to help accomplish our mission of establishing REMUNE®'s clinical benefit."
Specifically, the trial -- which was investigator-initiated and designed, double blinded and placebo-controlled -- demonstrated the induction of HIV-specific lymphocyte proliferation in all the chronically infected subjects who received REMUNE® and in none of those who received placebo. A total of 10 subjects participated, all of whom had viral loads controlled to less than 500 copies/ml for at least six months and CD4 cell counts of greater than 250 cells/mrn before starting ART.
While The Immune Response Corporation provided financial support and some reagents for the trial, the investigators generated, maintained and analyzed all related data using rigorous, prospectively defined criteria. The Immune Response Corporation did not participate in the preparation of the manuscript.
Trial data was originally presented at the XIV International AIDS Conference in Barcelona, Spain.
About The Immune Response Corporation and REMUNE®
Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company dedicated to treating HIV and AIDS through the development of REMUNE®. REMUNE® is an immune-based therapeutic vaccine designed to induce an HIV-specific immune response and boost the body's natural defense mechanisms in order to slow the virus' progression. REMUNE® is comprised of HIV that has been chemically killed and inactivated so that it is non-infectious. During the inactivation process, the HIV outer envelope, which is prone to rapid mutations, is removed. REMUNE® is then emulsified in Incomplete Freund's Adjuvant, an agent that elicits a more potent immune response by drawing the immune system's attention to the inactivated virus.
HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body's immune system, making it vulnerable to infections. More than 60 million people have been infected with HIV since it was first recognized in 1981. Today, 40 million people around the world are living with HIV.
QADSAN
